BRAF and cancer: These decreases were observed in both BRAF- and NRAS-mutated arms, and were moderate and consistent with observations in other cancer studies with MEK inhibitors, such as the observed suppression of pERK by cobimetinib (GDC-0973) both in vitro and in vivo [32].